Who are FluMist Quadrivalent (2017-2018)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): adjuvanted Arepanrix, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA, Assorted Licensed Hand Sanitizer Grape 01, PF-07852352 Influenza saRNA 1, Fluad alone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flumist-quadrivalent-2017-2018.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

FluMist Quadrivalent (2017-2018) — Competitive Intelligence Brief

FluMist Quadrivalent (2017-2018) (FluMist Quadrivalent (2017-2018)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated influenza vaccine (LAIV). Area: Immunology.

marketed Live attenuated influenza vaccine (LAIV) Influenza virus Immunology Biologic Live · refreshed every 30 min

Target snapshot

FluMist Quadrivalent (2017-2018) (FluMist Quadrivalent (2017-2018)) — MedImmune LLC. FluMist Quadrivalent is a live attenuated influenza vaccine that stimulates an immune response in the nasal passages to prevent influenza infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FluMist Quadrivalent (2017-2018) TARGET	FluMist Quadrivalent (2017-2018)	MedImmune LLC	marketed	Live attenuated influenza vaccine (LAIV)	Influenza virus
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
PF-07914705 Influenza saRNA	pf-07914705-influenza-sarna	Pfizer	marketed	RNA-based therapy	influenza virus
PF-07915048 Influenza saRNA	pf-07915048-influenza-sarna	Pfizer	marketed	RNA-based therapy	influenza virus
Assorted Licensed Hand Sanitizer Grape 01	Licensed Influenza Vaccine 3	BioNTech	marketed	Vaccine	Influenza virus hemagglutinin protein
PF-07852352 Influenza saRNA 1	pf-07852352-influenza-sarna-1	Pfizer	marketed	antisense oligonucleotide	influenza virus
Fluad alone	Fluad alone	Korea University Guro Hospital	marketed	Inactivated influenza vaccine with adjuvant	Influenza virus hemagglutinin and neuraminidase antigens; MF59 acts as immunological adjuvant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated influenza vaccine (LAIV) class)

MedImmune LLC · 7 drugs in this class
Altimmune, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FluMist Quadrivalent (2017-2018) — Competitive Intelligence Brief. https://druglandscape.com/ci/flumist-quadrivalent-2017-2018. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab